Study of Improving Insulin Sensitivity by Electroacupuncture Therapy

Study of Improving Insulin Sensitivity by Combined Both Electroacupuncture and Drug Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00379379

Enrollment

Registered

2006-09-21

Start date

2005-01-31

Completion date

2005-12-31

Last updated

2006-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Insulin Resistance

Keywords

electroacupuncture, plasma glucose, plasma insulin

Brief summary

The aim of this study is to find out whether the hypoglycemic and improving insulin resistance effect will appear or not, when EA applying on specific acupoints of NIDDM patients.

Detailed description

Some previous animal model studies reveal that electroacupuncture (EA) applying on specific acupoints, such as Zhongwan and Zusanli acupoint, can reduce plasma glucose levels and encourage insulin secretion, even improve insulin resistance. In this study, we want to observe these results on type II diabetic patients who have been diagnosed in five years under a study design of randomized control trial (RCT) to obtain evidence on clinical. We undertook a randomized, single blind and sham group controlled study to evaluate the effect of EA with a frequency in 15 Hz and fixed intensity (10 mA) on human Zusanli acupoint. A total of 26 newly diagnostic type II diabetic patients are enrolled in this study. They are randomly divided into 2 groups. There are 13 patients in the experimental group (EG) with EA treatment, and the other 13 patients are divided into control group (CG) with sham treatment. The main outcome is the changes of laboratory parameters between before and 30 minutes after the test.

Interventions

DEVICEelectroacupuncture

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

30 Years to 65 Years

Healthy volunteers

Inclusion criteria

* newly diagnosed NIDDM patient within 5 years * age between 30 to 65 years old * controlled BP below 140/90 mmHg * oral hypoglycemic agent (OHA) therapy with Gliclazide twice per day.

Exclusion criteria

* disorders of hemostasis * patient had received insulin therapy * severe disease such as CVA, CAD within 6 months * Arrhythmia history and on pacemaker.

Design outcomes

Primary

Measure	Time frame
Hypoglycemic activity, plasma insulin level, HOMA index	—

Secondary

Measure	Time frame
Triglyceride, cholesterol, free fatty acid	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026